214360-51-7

Basic information

• Product Name: 4-SULFAMOYLPHENYLBORONIC ACID, PINACOL ESTER
• Synonyms: 4-SULFAMOYLPHENYLBORONIC ACID, PINACOL ESTER;BENZENESULFONAMIDE-4-BORONIC ACID PINACOL ESTER;4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)benzenesulfonamide;4-Boronobenzenesulfonamide,pinacol ester;Benzenesulfonamide-4-boronic acid pinacol ester ,98%;4-Sulphamoylbenzeneboronic acid, pinacol ester;4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulphonamide;3-hydroxy-2,3-dimethylbutan-2-yl hydrogen (4-sulfamoylphenyl)boronate
• CAS NO: 214360-51-7
• Molecular Formula: C₁₂H₁₈BNO₄S
• Molecular Weight: 283.15
• Product Categories: Aryl;Organoborons;Sulfonamide;Amines;Boron Derivatives;Intermediates;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds
• Mol File: 214360-51-7.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 427.143 °C at 760 mmHg
• Flash Point: 212.129 °C
• Appearance: /
• Density: 1.242 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.543
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 10.00±0.10(Predicted)
• CAS DataBase Reference: 4-SULFAMOYLPHENYLBORONIC ACID, PINACOL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-SULFAMOYLPHENYLBORONIC ACID, PINACOL ESTER(214360-51-7)
• EPA Substance Registry System: 4-SULFAMOYLPHENYLBORONIC ACID, PINACOL ESTER(214360-51-7)

Safety Data

• Hazardous Substances Data: 214360-51-7(Hazardous Substances Data)

Usage

Uses

4-SULFAMOYLPHENYLBORONIC ACID, PINACOL ESTER is used for preparation of Valdecoxib.

InChI:InChI=1/C12H18BNO4S/c1-11(2)12(3,4)18-13(17-11)9-5-7-10(8-6-9)19(14,15)16/h5-8H,1-4H3,(H2,14,15,16)

Upstream product

• 701-34-8 4-bromo-benzenesulfonic acid amide 
• 73183-34-3 bis(pinacol)diborane 
• 98-58-8 4-bromobenzenesulfonyl chloride 
• 76-09-5 2,3-dimethyl-2,3-butane diol 
• 63-74-1 sulfanilamide 

Downstream Products

• 1332449-79-2 2'-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)biphenyl-4-sulfonamide 
• 1332449-69-0 3'-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)biphenyl-4-sulfonamide 
• 1332449-47-4 4-(6-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)pyridin-3-yl)benzenesulfonamide 
• 1614245-69-0 5'-(7-ethyl-7H-imidazo[4,5-c]pyridazin-4-yl)-2'-fluorobiphenyl-4-sulfonamide 
• 1473452-25-3 4-(3-methyl-4-oxo-4,5,6,7-tetrahydro-2H-isoindol-1-yl)benzenesulfonamide 
• 1366131-28-3 4-(2-amino-6-chloro-3-quinolinyl)benzenesulfonamide 
• 1246765-71-8 (R)-4-(1-(5-cyano-6-methylpyridin-2-yl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)benzenesulfonamide 
• 1215006-89-5 C₁₆H₁₆N₄O₃S 
• 1148110-23-9 4-[7-(4-piperidinyloxy)-6-isoquinolinyl]benzenesulfonamide 
• 1152473-58-9 4-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)benzenesulfonamide 
• 1059170-80-7 4-(3-cyano-1H-pyrrolo[2,3-b]pyridin-5-yl)benzenesulfonamide 
• 1022981-65-2 4-(6-{[(3-fluorophenyl)methyl]amino}imidazo[1,2-b]pyridazin-3-yl)benzene-1-sulfonamide 
• 1071766-98-7 3'-(8-Methyl-4-oxo-7-trifluoromethyl-4,5-dihydro-3H-benzo[b][1,4]diazepin-2-yl)-biphenyl-4-sulfonic acid amide 

Relevant articles and documents

Rational Design, Optimization, and Biological Evaluation of Novel MEK4 Inhibitors against Pancreatic Adenocarcinoma

Growth, division, and development of healthy cells relies on efficient response to environmental survival cues. The conserved mitogen-activated protein kinase (MAPK) family of pathways interface extracellular stimuli to intracellular processes for this purpose. Within these pathways, the MEK family has been identified as a target of interest due to its clinical relevance. Particularly, MEK4 has drawn recent attention for its indications in pancreatic and prostate cancers. Here, we report two potent MEK4 inhibitors demonstrating significant reduction of phospho-JNK and antiproliferative properties against pancreatic cancer cell lines. Furthermore, molecular inhibition of MEK4 pathway activates the MEK1/2 pathway, with the combination of MEK1/2 and MEK4 inhibitors demonstrating synergistic effects against pancreatic cancer cells. Our inhibitors provided insight into the crosstalk between MAPK pathways and new tools for elucidating the roles of MEK4 in disease states, findings which will pave the way for better understanding of the MAPK pathways and development of additional probes.

IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER

Disclosed are compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, disclosed are compounds of Formula (I) and pharmaceutical compositions thereof, and methods of using the compounds and pharmaceutical compositions in, for example, methods of treating cancer.

Discovery and evaluation of 3,5-disubstituted indole derivatives as Pim kinase inhibitors

Pim kinases are promising therapeutic targets for the treatment of hematological cancers. A potent Pim kinase inhibitor 7f, derived from meridianin C, was further optimized by the replacement of 2-aminopyrimidine with substituted benzene. The optimization of the C-3 and C-5 positions of indole yielded compound 43 with improved cellular potency and high selectivity against a panel of 14 different kinases.